Strides Pharma Science (NSE:STAR) PEG Ratio: N/A (As of Jun. 30, 2026)


NSE:STAR Strides Pharma Science Ltd NSE:STAR
67 GF Score
Price ₹1,103.40
GF Value ₹773.22
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strides Pharma Science PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Strides Pharma Science's PE Ratio without NRI is 17.55. Strides Pharma Science's 5-Year EBITDA growth rate is 0.00%. Therefore, Strides Pharma Science's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Strides Pharma Science's PEG Ratio or its related term are showing as below:



NSE:STAR's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.695
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Strides Pharma Science  (NSE:STAR) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Strides Pharma Science PEG Ratio Related Terms


Strides Pharma Science PEG Ratio Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science PEG Ratio Chart

Strides Pharma Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Strides Pharma Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:STAR vs ZTS, UTHR: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's PEG Ratio falls into.


NSE:STAR
67GF Score
Strides Pharma Science Ltd NSE:STAR
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strides Pharma Science PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Strides Pharma Science's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=17.554968657524/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,103.40 is trading 42.7% above its estimated GF Value™ of ₹773.22. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • PEG Ratio: N/A
  • GF Value™: ₹773.22 vs. price of ₹1,103.40 (42.7% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
67GF Score

Get the complete analysis for NSE:STAR

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,103.40
Price
₹773.22
GF Value